Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Oct 6;12(10):1561-1562.
doi: 10.2215/CJN.09040817. Epub 2017 Sep 18.

Rethinking End Points in Clinical Trials of Renoprotective Medication

Aliza Thompson  1
Affiliations
Editorial

Rethinking End Points in Clinical Trials of Renoprotective Medication

Aliza Thompson. Clin J Am Soc Nephrol. .
No abstract available

Keywords: Clinical Trials; Endpoint Determination; Renoprotective Medication.

PubMed Disclaimer

Comment on

References

    1. Weldegiogis M, de Zeeuw D, Dwyer J, Mol P, Lambers Heerspink H: Is chronic dialysis the right hard renal endpoint to evaluate renoprotective drug effects? Clin J Am Soc Nephrol 12: 1595–1600, 2017 - PMC - PubMed
    1. CFAST Diabetic Kidney Disease Team: Therapeutic Area Data Standards User Guide for Diabetic Kidney Disease Version 1.0 (Provisional), 2016. Available at: https://www.cdisc.org/standards/therapeutic-areas/diabetic-kidney-disease. Accessed August 28, 2017
    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001 - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001 - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3(Suppl): 1–150, 2013.